Myleran is the brand name for a medication containing the active ingredient busulfan. Busulfan is a chemotherapy agent used in the treatment of certain types of cancer, particularly hematologic malignancies. Here is a detailed description of Myleran (Busulfan) 2 mg tablets:

Active Ingredient:

• Busulfan: Busulfan is an alkylating agent that interferes with the DNA synthesis process, inhibiting the growth of cancer cells. It is commonly used in the treatment of chronic myeloid leukemia (CML) and other hematologic conditions.

Indications:

• Myleran is primarily indicated for the treatment of chronic myeloid leukemia (CML), a type of cancer that affects the blood and bone marrow. It may be used as part of a combination therapy or alone, depending on the specific treatment plan recommended by the healthcare provider.

Dosage and Administration:

• Myleran is typically administered orally in the form of tablets. The dosage and treatment schedule are determined by the healthcare provider based on the type and stage of cancer, the patient’s overall health, and other factors.

Mechanism of Action:

• Busulfan works by attaching to DNA and interfering with its structure and function. This interference prevents the cancer cells from dividing and multiplying, ultimately leading to a reduction in the number of cancer cells.

Side Effects:

• Common side effects of Myleran may include nausea, vomiting, diarrhea, loss of appetite, and skin rash. Busulfan can also affect the bone marrow, leading to low blood cell counts (anemia, neutropenia, thrombocytopenia). Patients should report any severe or persistent side effects to their healthcare providers.

Precautions and Monitoring:

• Regular blood tests are typically conducted during Myleran treatment to monitor blood cell counts, liver function, and other parameters. Patients may also undergo periodic bone marrow examinations to assess treatment response.

Contraindications:

• Myleran is contraindicated in individuals with a known hypersensitivity to busulfan or any of the components in the formulation. It is also contraindicated in patients with a history of seizures or severe bone marrow suppression.

Pregnancy and Breastfeeding:

• Myleran can cause harm to a developing fetus, and women are advised to use effective contraception during treatment and for a period after the last dose. Breastfeeding is not recommended during Myleran treatment.

Interactions:

• Busulfan may interact with certain medications, and patients should inform their healthcare providers about all prescription and over-the-counter drugs, as well as herbal supplements, they are taking.

Patients undergoing cancer treatment with Myleran should have open communication with their healthcare team, report any side effects promptly, and follow the recommended treatment plan. The information provided here is a general overview, and specific details may vary based on individual cases and healthcare provider recommendations.